Physiology Or Medicine Research Articles

The Nobel “Pride” Phenomenon: An analysis of Nobel Prize discoveries and their recognition

The Nobel Prize is considered one of the highest forms of recognition of scientific accomplishment, conferring immense prestige upon its recipients. Given the significant time lag between the award and the discovery, Nobel Prizes are bestowed to individuals associated with institutions and countries other than the original place of the discovery. Contextualizing our research in status-seeking literature, we define the imprecise and sometimes excessive appropriation of Nobel Prizes by institutions and even countries as the “Nobel ‘Pride’ Phenomenon”. Our empirical analysis focuses on the time and location of the 653 discoveries underlying each of the 350 Nobel Prizes in medicine, physics, and chemistry until 2024. About one-third of all Nobel laureates came from another institution or country. Furthermore, Nobel Prize creativity is highly concentrated, with more than 80 % of discoveries made in just five countries. These findings cast new light on the Nobel laureates' demographics, geographic and historical movements, and institutional affiliations, and have implications for research policy at institutions and national levels.

2023 Nobel Prize in Physics and Medicine

The 2023 Nobel Prize in Physiology and Medicine was awarded jointly to Katalin Karikó and Drew Weissman for their contributions to the development of mRNA vaccines against COVID-19. Dr. Karikó obtained her doctoral degree from the University of Szeged before moving to the United States and obtaining the position of an adjunct professor at the University of Pennsylvania.1 Dr. Weissman obtained an M.D. and a Ph.D. degree at Boston University and subsequently obtained a faculty position at the Perelman School of Medicine at the University of Pennsylvania. The two researchers met during their shared time at the University of Pennsylvania and collaborated in exploring mechanisms in which mRNA can be used to stimulate immunity development in the body.2 By modifying nucleotides in mRNAs, the pair discovered that the subsequent introduction of mRNAs into cells led to reduced inflammatory responses and increased immune protein production. Before the COVID-19 pandemic, most vaccines stimulated immune responses via attenuated viruses, proteins, or viral genetic code-carrying vectors. These vaccines, while effective, required substantial resources to produce the number of cell cultures needed to synthesize adequate supplies of vaccine to combat pandemics, such as COVID-19.3 Contrastingly, mRNA vaccines can be prepared without cell cultures through in vitro transcription and nucleotides can be modified to adapt to mutating pathogens - flexibilities that allowed more than 12 billion COVID-19 vaccines to be produced and administered in less than three years of the start of the pandemic.4,5

Life-threatening antibodies: The discovery of anaphylaxis.

It was at the turn of the 20th century, that immune serum was found both to save children dying from toxins of deadly pathogens, and to kill a dog within minutes following an injection of harmless doses of sea anemone toxins. This means that, before being formally identified in immune serum, antibodies were already known to be both protective and pathogenic. For this provocative finding, Charles Richet was awarded the 1913 Nobel Prize in Physiology or Medicine. Because, as its name said, anaphylaxis was understood as "the contrary of protection," unique mechanisms were found to explain it. Because, as its name did not initially say but finally said, allergy was understood as a reaction "other" than immunity, its symptoms were explained by mechanisms similar to those that explained anaphylaxis. We examined here the intricate relationships between anaphylaxis, allergy and immunity. Progressively anaphylaxis became one among other pathological effects of an immune response, and allergy an inflammatory disease among others. Looking at antibodies back in the past enables us not only to learn where they come from, but also to follow trends that contributed to shape immunology, some of which may persist in today's immunological thinking and say something about the future.

The 75-Year Anniversary of the Department of Physiology and Pharmacology at Karolinska Institutet-Examples of Recent Accomplishments and Future Perspectives.

Karolinska Institutet is a medical university encompassing 21 departments distributed across three departmental or campus groups. Pharmacological research has a long and successful tradition at the institute with a multitude of seminal findings in the areas of neuronal control of vasodilatation, cardiovascular pharmacology, neuropsychopharmacology, receptor pharmacology, and pharmacogenomics that resulted in, among many other recognitions, two Nobel prizes in Physiology and Medicine, one in 1970 to Ulf von Euler for his discovery of the processes involved in storage, release, and inactivation of neurotransmitters and the other in 1982 to Sune Bergström and Bengt Samuelsson for their work on prostaglandins and the discovery of leukotrienes. Pharmacology at Karolinska Institutet has over the last decade been ranked globally among the top 10 according to the QS World University Ranking. With the Department of Physiology and Pharmacology now celebrating its 75-year anniversary, we wanted to take this as an opportunity to showcase recent research achievements and how they paved the way for current activities at the department. We emphasize examples from preclinical and clinical research where the dpartment's integrative environment and robust infrastructure have successfully facilitated the translation of findings into clinical applications and patient benefits. The close collaboration between preclinical scientists and clinical researchers across various disciplines, along with a strong network of partnerships within the department and beyond, positions us to continue leading world-class pharmacological research at the Department of Physiology and Pharmacology for decades to come. SIGNIFICANCE STATEMENT: Pharmacological research at Karolinska Institutet has a long and successful history. Given the 75-year anniversary of the Department of Physiology and Pharmacology, this perspective provides an overview of recent departmental achievements and future trajectories. For these developments, interdisciplinary and intersectoral collaborations and a clear focus on result translation are key elements to continue its legacy of world-leading pharmacological research.

Nobel Prize in Physiology or Medicine for microRNA

Nobel Prize in Physiology or Medicine for microRNA

Outstanding Scientist I. Ya. Horbachevsky (dedicated to the 170th birth anniversary)

Ivan Yakovych Horbachevsky is one of the outstanding scientists of world science, whose activities span the middle of the 20th century. He, our compatriot, comes from the village Zarubyntsi, Ternopil region. The numerous scientific and governmental titles, ranks and awards that he was awarded confirm Ivan Horbachevsky’s global authority and popularity. He was elected honorary president of international scientific forums and congresses. He was also entrusted with the most difficult tasks in medicine and education. The scientist brought recognition to University of Vienna. He was elected a member (and later chairman) of the Royal Sanitary Council, given several high titles and appointed the first minister of health in Austria-Hungary. Ivan Horbachevsky’s scientific heritage includes more than 50 works published in German, Czech and Ukrainian languages (only 6 of them were in Ukrainian). He proposed the nomenclature of organic (1924–1926) and inorganic compounds (1939–1941), which formed the basis of the chemical substance classification and nomenclature. His nomenclature was implemented in Ukraine before World War II. Ivan Yakovych Horbachevsky was a candidate for the Nobel Prize in Physiology and Medicine in 1911. He lived for 67 years outside of his motherland, but he was closely connected with Ukraine, and did a lot for our state independence.

Rita Levi-Montalcini: From Persecution to the Nobel Prize and an Honorary Degree From a Canadian University.

Rita Levi-Montalcini (RLM) is recognized as a prestigious and renowned researcher of her time. She was the fourth woman to earn the Nobel Prize in Physiology and Medicine in 1986 for the discovery of nerve growth factor (NGF). We review her biography and scientific discovery, and provide an example of why her discovery is still important. She had a special relationship with McGill University, Canada, which we describe. We searched for articles and books about her for biographical and scientific material and met with Dr. Claudio Cuello, Former Chair of McGill's Faculty of Medicine. RLM was born in 1909 in Turin, Italy, where she had studied medicine. She started her career in research. Because of the anti-Jewish racial laws in Italy in 1938, she went underground and continued her projects in her bedroom. After the war, she visited St. Louis, USA, and conducted research there. Her experiments confirmed that tumors release a factor that causes nerve growth and cancer proliferation. Initially, scientists responded to this discovery with skepticism, but after its purification in 1959 and determination of its protein structure in 1971, NGF became widely accepted.Currently, crosstalk between cancers and nerves is poorly understood. The example of prostate cancer shows that surgical or chemical denervation of sympathetic nerves prevents the initiation of prostate tumors, whereas inhibition of parasympathetic nerve signaling reduces the spread of prostate cancer. McGill University awarded RLMa doctoral degree in 2011. It was the first time in itshistory that the University awarded an honorary doctorate outside of Canada, and the second one outside of Quebec.Through her discovery of NGF, RLM exemplified the power of passion and determination despite the obstacles she faced. Her relentless dedication has led to remarkable achievements.

Karl Landsteiner (1868-1943): A Versatile Blood Scientist.

Karl Landsteiner (1868-1943) was an Austrian-American biologist, physician, and immunologist whose groundbreaking discoveries revolutionized the fields of transfusion medicine, immunology, and virology. His most famous work was the identification of the ABO blood group system in 1901, which explained the causes of transfusion reactions and laid the foundation for safe blood transfusions. This discovery earned him the Nobel Prize in Physiology or Medicine in 1930. Landsteiner continued his research, identifying the MN and P blood group system in 1927 and the Rh blood group system in 1940, which addressed the complexities of the Hemolytic Disease of the Fetus and Newborn (HDFN). His work on the poliovirus in 1908, in collaboration with Erwin Popper, established the infectious nature of the disease and laid the groundwork for future vaccine development. Landsteiner's versatility as a scientist is evident in the breadth of his work, spanning hematology, immunology, and virology. His ability to navigate diverse fields and see connections between them allowed him to make pioneering discoveries that have had a lasting impact on medical practice, particularly in blood transfusion, organ transplantation, and immunotherapy. Landsteiner's legacy as the "Father of Transfusion Medicine" is reinforced by the standardization of blood typing procedures, which have saved millions of lives worldwide.

The Gerty Cori phenomenon: the first woman Nobel laureate in Physiology and Medicine

Gerty Cori was the first woman awarded the Nobel Prize in Physiology or Medicine, the first woman the Nobel Prize laureate in the United States, and the third woman the Nobel Prize laureate worldwide following Marie Curie-Skłodowska and her daughter, Irene Joliot-Curie. Despite a challenging and lengthy path to recognition, Gerty Cori’s exceptional qualities and strong character led to her success. In 1947, she was awarded the Nobel Prize in Physiology or Medicine jointly with her husband and lifelong research partner Carl Cori “for their discovery of the course of the catalytic conversion of glycogen”. The Nobel Committee recognized this discovery as one of the most outstanding achievements in biochemistry. Keywords: adrenaline, Cori cycle, diabetes, glucose, glucose-1-phosphate, glucose-6-phosphate, glycogen, hexokinase, insulin, Nobel Prize, phosphoglucomutase, phosphorylase

Breaking Barriers: The Life and Legacy of Gerty Cori in Biochemical Research.

Gerty Theresa Cori, a remarkable and pioneering biochemist, became the first woman to receive the Nobel Prize in Physiology or Medicine in 1947 for her groundbreaking research in carbohydrate metabolism. Her work, in collaboration with her husband Carl Ferdinand Cori, revolutionized the scientific understanding of carbohydrate metabolism and had a profound impact on medicine and human health. This paper offers a historical vignette of Gerty Cori's life, tracing her journey from her early years in Prague to her pivotal role in transforming biochemistry. It highlights her immense dedication to scientific research, overcoming significant gender-based challenges, and establishing a legacy that continues to inspire. Gerty Cori's contributions to science not only advanced our knowledge of metabolic processes but also paved the way for future generations of researchers, particularly women in science, technology, engineering, and mathematics.

Three Dermatologists Who Were Nominated for a Nobel Prize: Albert Neisser, Erich Hoffmann, and Aaron B. Lerner

During the past 125 years, three dermatologists have been nominated for the Nobel Prize in Physiology or Medicine: Albert Neisser (1855-1916), Erich Hoffmann (1868-1959), and Aaron B. Lerner (1920-2007). Neisser was nominated 22 times for his discovery of the gonococcus and for his work on the serologic testing for syphilis through complement fixation. Hoffman was nominated three times for his role in the discovery of Treponema pallidum. Lerner was nominated twice, once for his work on melanocyte-stimulating hormone and a second time for his work on melatonin.Although neither Neisser, Hoffmann, nor Lerner won the Nobel Prize, it is still a notable accomplishment that each of them was nominated multiple times for this prestigiousaward. This contribution highlights the lives and careers of these three distinguished dermatologists, including the landmark discoveries they made that led to their being nominated for a Nobel Prize.

Allvar Gullstrand: The Only Ophthalmologist Who Won the Nobel Prize.

Allvar Gullstrand, the Swedish ophthalmologistand Nobel laureate, was a self-taught mathematician who applied mathematics and higher-order equations to understand the optic system. His inventions, the slit lamp, and the ophthalmoscopeareused in clinical practice for the diagnosis of eye diseases. With his efforts, he explained the accommodation, the process of changing the shape of the lens to focus on near or distant objects.In 1911, he was awarded the Nobel Prize in Physiology or Medicine. In 1913, he was elected as the first president of the Swedish Ophthalmological Society. In 1927, he was awarded the Graefe Medal of the Deutsche Ophthalmologische Gesellschaft.

Surprising Wilkins’ error (Nature 1953, 172: 755–762)

The Nobel Prize in Physiology or Medicine 1962 was awarded jointly to Francis Harry Compton Crick, James Dewey Watson and Maurice Hugh Frederick Wilkins “for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material”. Building the scale atomic-molecular models and applying strong inference Watson and Crick (1953a,b) presented convincing evidences for the following features of the spatial structure of the DNA molecule: (i) this structure has two helical chains each coiled round the same axis; (ii) both chains follow right-handed helices; (iii) the sequences of the atoms in the two chains run in opposite directions; (iv) the two chains are held together by hydrogen-bonded purine and pyrimidine bases; (v) the planes of the bases are perpendicular to the fibre axis; (vi) only specific pairs of bases can bond together: adenine (purine) with thymine (pyrimidine), and guanine (purine) with cytosine (pyrimidine). X-ray evidence obtained at the same time by Wilkins et al. (1953a,b), and Franklin et al. (1953a,b) gave qualitative support to this structure and was incompatible with all previously proposed structures. Wilkins et al. (1953b) built molecular models of the type described by Watson and Crick (1953a) and adjusted them to conform with their experimental data. However, it appeared that the paper by Wilkins et al. (1953b) contains a curious and inexplicable error. Namely, in their Figure 3 DNA is schematically drawn as a left-handed helix, which, as Crick and Watson (1954) explained, is stereochemically impossible and must be right-handed. The fact stated here was mysteriously not noticed before and, fortunately, had no detrimental effect on the development of science.

Establishing a biochemical understanding of the initiation of chromosome replication in bacteria

In the mid-1950s, Arthur Kornberg elucidated the enzymatic synthesis of DNA by DNA polymerase, for which he was recognized with the 1959 Nobel Prize in Physiology or Medicine. He then identified many of the proteins that cooperate with DNA polymerase to replicate duplex DNA of small bacteriophages. However, one major unanswered problem was understanding the mechanism and control of the initiation of chromosome replication in bacteria. In a seminal paper in 1981, Fuller, Kaguni, and Kornberg reported the development of a cell-free enzyme system that could replicate DNA that was dependent on the bacterial origin of DNA replication, oriC. This advance opened the door to a flurry of discoveries and important papers that elucidated the process and control of initiation of chromosome replication in bacteria.

100 Years since Robert Barany's visit to the Zaragoza medical faculty.

In December 1923, a twelve-day course took place at the University of Zaragoza, specifically at the Faculty of Medicine, given by Professor Róbert Bárány, who was awarded the Nobel Prize for Medicine in 1914 for his discoveries on the vestibular apparatus. Professor Robert Bárány came to the faculty at the invitation of Professor Victor Fairén through the University Exchange programme. This course consisted of four lectures and twelve lessons a day in which he presented his knowledge of the physiopathology of the vestibule and cerebellum, as well as practical demonstrations of the physical examination of nystagmus and cerebellar pathology. Lorente de Nó, a doctorate student of medicine, was one of the most outstanding students on the course. His intellect was already outstanding in those years, which helped him to discuss the physiopathology of nystagmus with Professor Bárány. The relationship he forged with the Nobel laureate in Zaragoza would be decisive for his future as a researcher. The aim of this work is to compile and integrate the available information on the course that Professor Bárány took in the city of Zaragoza, consulting official documents from the university and the city, articles, books and the press of the time.

The development of innovative therapeutic drugs targeting hypoxia responses

The 2019 Nobel Prize in Physiology or Medicine was awarded to Dr. William G. Kaelin Jr, Dr. Peter J. Ratcliffe, and Dr. Gregg L. Semenza for their elucidation of new physiological mechanisms "How cells sense and adapt to oxygen availability". Moreover, two different drugs, HIF-PH inhibitors and HIF-2 inhibitors were also developed based on the discovery. Interestingly, those three doctors have different backgrounds as a medical oncologist, a nephrologist, and a pediatrician, respectively. They have started the research based on their own unique perspectives and eventually merged as "the elucidation of the response mechanism of living organisms to hypoxic environments". In this review, we will explain how the translational research that has begun to solve unmet clinical needs successfully contributed to the development of innovative therapeutic drugs.

Clinical application and future perspectives of HIF-PH inhibitors

Anemia in chronic kidney disease (CKD) occurs due to insufficient production of erythropoietin to compensate for the decrease in hemoglobin. Anemia in CKD has traditionally been treated with periodic injections of erythropoiesis-stimulating agents (ESAs), which are recombinant human erythropoietin preparations. Although ESA improved anemia in CKD and dramatically improved the quality of life of patients, there are some patients who are hyporesponsive to ESA, and the use of large doses of ESA in these patients may have a negative impact on patient prognosis. Currently, HIF prolyl hydroxylase (HIF-PH) inhibitors have been approved in Japan as a new treatment for anemia in CKD. HIF-PH inhibitors activate HIF and promote the production of endogenous erythropoietin. The 2019 Nobel Prize in Physiology or Medicine was awarded for groundbreaking research that uncovered the HIF pathway. Because HIF-PH inhibitors improve both erythropoietin production and iron metabolism, they are expected to be effective in treating ESA hyporesponsiveness and solve the inconvenience of injectable preparations. On the other hand, its effects are systemic and multifaceted, and long-term effects must be closely monitored.

Bibliometric comparison of Nobel Prize laureates in physiology or medicine and chemistry

The Nobel Prize is an annual honor awarded to the researchers who have made the greatest contribution to humanity with their work in the year in question. Nobel Prizes for physiology or medicine and chemistry most often have direct or indirect pharmacological relevance. In this study, we performed a bibliometric analysis of Nobel Prize laureates from 2006 to 2022. The parameters include the nationalities and age of the laureates, age at their productivity peaks, the research locations, the H-index, the age-adjusted H-index, and the number of citations and publications, and, for each parameter, a comparison of female and male award laureates. Men were much more often awarded the Nobel Prize than women. Surprisingly, women were younger than their male colleagues at the time of the award although the productivity peak was similar. There was a correlation between all publications and the H-index, which was slightly stronger for women than for men. The age-adjusted H-index showed no difference among genders. The USA were the country with the highest number of Nobel Prize laureates, both male and female. Overall, the bibliometric characteristics of male and female Nobel Prize laureates are similar, indicating that among the group of Nobel Prize laureates, there is no bias against women. Rather, the achievements of women are recognized earlier than those of men. The major difference is that the number of women becoming Nobel Prize laureates is much smaller than the number of men. This study provides a starting for future studies with larger populations of scientists to analyze disparities.

Roger Sperry, the maverick brain scientist who was haunted by psyche.

This paper describes the scientific figure of Roger Sperry as a maverick researcher, an original thinker who arrived at definitive notions about the working of the brain mostly by distancing himself from the prevalent views of his peers. After solving the riddle of the functions of the corpus callosum, he won a Nobel prize in physiology or medicine for identifying the different cognitive abilities of the disconnected right and left hemispheres of the human brain. He could have won another Nobel prize for his work on the prenatal formation of behavioral neuronal networks and their growth and development after birth. In the last part of his life, he fought a courageous but inconclusive battle for demonstrating that mental and spiritual factors can direct brain activity and behavior without violating the laws of orthodox neurophysiology. Some nodal points in his scientific career and some sources of inspirations for his thinking are identified and discussed within the historical background of the neurosciences of the twentieth century.

Artemisia spp. Essential Oils: From Their Ethnobotanical Use to Unraveling the Microbiota Modulation Potential.

The 2015 Nobel Prize in Medicine, awarded for the discovery of artemisinin in Artemisia annua, reignited interest in aromatic plants, including Artemisia absinthium L. This article delves into the historical, ethnopharmacological and medicinal significance of A. absinthium, examining its bitter taste noted since ancient Greek times and its association with medicinal properties throughout history. Despite being banned in the 20th century due to perceived health risks; recent research has led to the reconsideration of A. absinthium's potential applications. This study focuses on the prebiotic efficacy of essential oils (EOs) from two Artemisia species: A. absinthium and A. annua. A broth microdilution test, growth curve test and in vivo models were used to study the impact of low doses (from 0.5% v/v to 0.00048 v/v) of Artemisia spp-EO on the three probiotic strains (Lactobacillus, Lactobacillus casei and Saccharomyces boulardii). These essential oils, when used in minimal concentrations (lower than 0.06% v/v), are safe and exhibit prebiotic effects on major probiotic strains, supporting the traditional culinary use of Artemisia spp. This research opens avenues for potential applications in the food industry, emphasizing the need for further exploration into the prebiotic properties of Artemisia spp-EOs and their influence on the microbiota.